ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Anaplastic thyroid cancer (ATC) is a highly aggressive malignancy with limited treatment options and poor prognosis.
• Genetic alterations, including PI3K/MAPK/ERK pathway activation and p53 loss, are common in ATC.
• Mutations and rearrangements in the anaplastic lymphoma kinase (ALK) gene are implicated in ATC development.

Purpose of the Study:

• To investigate the role of ALK mutations in ATC development.
• To evaluate the efficacy of ALK inhibition as a therapeutic strategy for ATC.
• To establish and characterize a novel mouse model for studying ATC.

Main Methods:

• Generated a mouse model (Trp53^KO/ALK^F1174L) with inducible thyrocyte-specific expression of mutant ALK and p53 deletion.
• Established primary thyroid cancer cell lines from the mouse model.
• Assessed the effects of ALK inhibition using the inhibitor TAE-684 in vitro and in vivo.

Main Results:

• Trp53^KO/ALK^F1174L mice developed locally invasive and metastatic ATC with reduced survival.
• ALK inhibition decreased AKT/ERK phosphorylation and induced cytotoxicity in ATC cells.
• Treatment with TAE-684 significantly extended median survival in the mouse model (66 days vs. 18 days).

Conclusions:

• The combination of ALK^F1174L mutation and Trp53 loss drives ATC development.
• This study provides the first functional evidence supporting ALK inhibitors for ALK-driven ATC.
• The developed mouse model and cell lines are valuable tools for ATC research and therapeutic development.